Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Vernier, US
Jean-Michel Vernier, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080312286 | Indanone Potentiators of Metabotropic Glutamate Receptors - The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 12-18-2008 |
| 20090162319 | REVERSE TRANSCRIPTASE INHIBITORS - Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV reverse transcriptase as a method of treating or preventing HIV, AIDS or related disorders. | 06-25-2009 |
| 20100056464 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 03-04-2010 |
| 20100056465 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 03-04-2010 |
| 20110098291 | ANTAGONIST OF SMOOTHENED - Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary diseases and disorders. | 04-28-2011 |
| 20110166123 | NOVEL COMPOSITIONS AND METHODS OF USE - Described herein are novel enzyme inhibitors. In some embodiments the enzyme inhibitors are integrase inhibitors, particularly HIV integrase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV integrase as a method of treating or preventing HIV, AIDS or related disorders. | 07-07-2011 |
P. Thomas Vernier, Los Angeles, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090143718 | PLASMA TREATMENT PROBE - A plasma treatment probe may include a hollow, tubular electrode defining an interior region, and a coaxial insulating tube configured to enclose the electrode. The insulating tube may form a gas flow outlet at one end. An outer chamber may enclose the insulating tube and the hollow electrode, and may have a gas inlet for receiving a gas mixture. The hollow electrode may be configured to receive nanosecond electric pulses, while a gas mixture flows from the gas inlet through the interior region of the electrode, so that a non-thermal plasma can be ignited that exits from the gas flow outlet onto a region of a patient's body to medically treat the region. | 06-04-2009 |
Steve Vernier, Phoenix, AZ US
| Patent application number | Description | Published |
|---|---|---|
| 20090256674 | Programmable Selective Wake-Up for Radio Frequency Transponder - A remote keyless entry (RKE) transponder has a programmable selective wake-up filter for determining whether the RKE transponder should wake-up to process a received signal. The wake-up filter correlates the timing of an input signal's carrier amplitude on and off time periods to a predefined programmable time period profile for a desired signal which has a certain carrier on time (time period on) and a certain carrier off time (time period off) arranged into a coded “header.” When a received signal matches the predefined time period profile, then the RKE transponder will wake-up to process the incoming signal data. The predefined time period profile may be programmable and may be stored in a header configuration register. Each RKE transponder has unique predefined time period on and time period off profiles. | 10-15-2009 |
William F. Vernier, St Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20090156685 | (R)-CHIRAL HALOGENATED SUBSTITUTED FUSED HETEROCYCLIC AMINO COMPOUNDS USEFUL FOR INHIBITING CHOLESTEROL ESTER TRANSFER PROTEIN ACTIVITY - The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. | 06-18-2009 |
William Francois Vernier, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110092590 | NITRIC OXIDE DONATING PROSTAMIDES - Nitroderivatives of prostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension. | 04-21-2011 |